TWiV 945: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Research assistant position with Amy Rosenfeld (pdf) Support MicrobeTV with a Spike t-shirt at Vaccinated.US A healthcare-associated infection with monkeypox virus (OFID) Air and surface sampling for monkeypox virus (The Lancet) Misrepresentation & nonadherence in COVID-19 public health measures (JAMA) Tolerability and immunogenicity of a COVID-19 vaccine (The Lancet) PAXLOVID patient eligibility screening checklist (FDA) Evaluation of symptomatic disease rebound following PAXLOVID (CID) Outpatient treatment with Remdesivir in patients at high risk (OFID) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Molnupiravir as early treatment for adults with COVID-19 (SSRN) Outcomes among confirmed cases and matched comparison group in long-COVID (Nature) Dr. Griffin’s treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 945 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]